Table 2 Summary of cost-effectiveness analysis results

Base-case analysis

BSC

41,242

0.39

0.69

/

/

TAS-102

140,656

0.68

1.10

349,254

/

REDo

177,069

0.59

0.99

682,534

dominated

Regorafenib

218,487

0.53

0.85

1,317,383

dominated

Fruquintinib

334,799

0.89

1.39

588,347

905,914

TAS-BEV

320,452

1.01

1.59

451,853

539,481

Scenario 1: Excluding Asian Trials

BSC

41,242

0.39

0.69

/

/

TAS-102

117,707

0.58

0.97

404,972

/

REDo

179,312

0.62

1.04

610,787

1,654,400

Regorafenib

193,508

0.52

0.85

1,154,533

dominated

Fruquintinib

265,279

0.76

1.22

611,923

832,311

TAS-BEV

453,092

1.47

2.43

382,009

377,134

Scenario 2: Time-invariant HR

BSC

41,242

0.39

0.69

--

--

TAS-102

90,440

0.57

1.00

280,550

--

REDo

159,849

0.84

1.51

261,924

250,152

Regorafenib

120,589

0.58

1.01

418,158

2,095,059

Fruquintinib

221,387

0.67

1.10

653,564

1,305,919

TAS-BEV

270,568

1.11

1.85

317,885

329,875

Scenario 3: Allowance for Active Treatment upon Disease Progression

BSC

41,242

0.39

0.69

/

/

TAS-102

179,335

0.68

1.10

485,140

--

REDo

204,790

0.59

0.99

821,831

dominated

Regorafenib

222,751

0.53

0.85

1,349,073

dominated

Fruquintinib

367,228

0.89

1.39

653,341

876,748

TAS-BEV

333,405

1.01

1.59

472,816

462,290

Scenario 4: Change utilities

BSC

41,242

0.45

0.69

/

/

TAS-102

140,656

0.76

1.10

321,344

/

REDo

177,069

0.66

0.99

620,769

dominated

Regorafenib

218,487

0.57

0.85

1,382,855

dominated

Fruquintinib

334,799

0.99

1.39

541,896

835,551

TAS-BEV

320,452

1.10

1.59

425,831

519,172

Scenario 5: Assuming cost of BSC to be 0

BSC

37,423

0.39

0.69

/

/

TAS-102

138,077

0.68

1.10

353,613

/

REDo

174,190

0.59

0.99

687,260

dominated

Regorafenib

218,044

0.53

0.85

1,342,479

dominated

Fruquintinib

332,132

0.89

1.39

590,656

905,500

TAS-BEV

319,589

1.01

1.59

456,637

544,627